
InhaTarget Thereapeutics
Founded Year
2018Stage
Series A | AliveTotal Raised
$6.12MLast Raised
$6.12M | 4 yrs agoAbout InhaTarget Thereapeutics
InhaTarget Therapeutics develops targeted dry powders for inhalation that aim to improve the treatment of severe and/or chronic respiratory diseases.
InhaTarget Thereapeutics Frequently Asked Questions (FAQ)
When was InhaTarget Thereapeutics founded?
InhaTarget Thereapeutics was founded in 2018.
Where is InhaTarget Thereapeutics's headquarters?
InhaTarget Thereapeutics's headquarters is located at Université libre de Bruxelles (ULB), Unité de Pharmacie galénique et de biopharmacie., Bruxelles.
What is InhaTarget Thereapeutics's latest funding round?
InhaTarget Thereapeutics's latest funding round is Series A.
How much did InhaTarget Thereapeutics raise?
InhaTarget Thereapeutics raised a total of $6.12M.
Who are the investors of InhaTarget Thereapeutics?
Investors of InhaTarget Thereapeutics include Theodorus, SMB Lab, Galephar Pharmaceutical Research and Sambrinvest.